A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.
Clascoterone has shown promising results in increasing hair density without systemic side effects, potentially offering benefits similar to finasteride. There is skepticism due to the lack of published photos despite the market interest.
The conversation discusses hair loss treatments, specifically oral Minoxidil, also known as Loniten or Alotendin in Bulgaria. It also mentions considering IndiaMart for purchasing options.
The conversation discusses using estradiol mesotherapy to replicate hormone replacement therapy results while minimizing systemic exposure. It also covers the use of Spironolactone cream, which reportedly has no systemic side effects, and the potential risks of using bicalutamide and Spironolactone in men.
The potential of using a specific antibody, HMI-115, as a treatment for hair loss alongside traditional treatments such as minoxidil and finasteride. The user suggests trying either a 240 mg or 30 mg dose to see if it works.
The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
The user experienced hair improvement using 1mg finasteride daily for six months, managing seborrheic dermatitis with rosemary and eucalyptus oil. They are considering switching to dutasteride for potentially better results.
RU58841 is not FDA approved, and users are discussing its availability and legitimacy in India, with some mentioning brands like Vantanex and Capomil. One user warns about the risk of gyno from RU58841, advising to stop use at the first sign of sensitivity.
A user was prescribed Alpicort E, which contains Estradiol Benzoate, Prednisone, and Salicylic Acid, for hair loss and is seeking others' experiences due to concerns about potential side effects.
RU58841 is discussed as a hair loss treatment, with users considering lower doses like 2.5% to reduce costs. Some users suggest that if already blocking DHT, lower doses might still be effective unless there's high sensitivity to DHT.
The user has been using minoxidil and finasteride for hair loss without positive results and switched to dutasteride 1.5 months ago. They suspect seborrheic dermatitis might be affecting the effectiveness of these treatments.
Cutting a 5 mg finasteride tablet into five equal parts and taking one piece daily is recommended for consistent dosing. This approach provides more stable DHT suppression than taking a full 5 mg tablet every five days.
A user is considering tapering off finasteride due to concerns about long-term side effects and cost, and is exploring alternatives like zinc and saw palmetto. Their current regimen includes finasteride, Adderall, zinc, bupropion, fish oil, baby aspirin, Rogaine foam, and ketoconazole shampoo.
A medical student experienced hair loss slowing with Finasteride but developed severe, treatment-resistant insomnia. They tried various medications with little effect, suspecting Post-Finasteride Syndrome, and others suggested the insomnia might be linked to Finasteride's impact on neurosteroids.
Finasteride is being considered for purchase in Turkey due to cheaper prices and availability compared to Hungary and Poland. The user seeks information on over-the-counter availability, pricing, and reliable pharmacies in Istanbul.
Breezula (clascoterone) is expected to be available by late 2026, showing good long-term results with minimal side effects. KX-826 (pyrilutamide) acts faster but is still in earlier development stages.
The user has been using pyrilutamide, topical finasteride, and 15% minoxidil for hair growth for almost 4 years. Despite mixed responses from others, the user reports seeing progress, especially with the addition of pyrilutamide, and plans to continue the regimen.
The user has been using topical finasteride since October without improvement and is considering adding a caffeine product with dimethylglycine. Another user suggests caffeine is more promising and advises consulting a dermatologist about the lack of progress with finasteride.
Hair loss discussion mentions Minoxidil, finasteride, and RU58841 treatments. Regenepure shampoo's ketoconazole ingredient causes confusion due to inconsistent listings.
TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.
A 23-year-old experienced severe depression and suicidal thoughts from oral finasteride and is considering trying topical finasteride but is worried about similar side effects. They are currently using RU58841 and Minoxidil and are seeking advice on the lowest effective dose of topical finasteride.
A 22-year-old male experienced hair loss potentially linked to escitalopram, which stopped after switching to vortioxetine. His depressive symptoms improved with continued treatment.
A 31-year-old male switched from topical to oral Minoxidil (2.5 mg) and Finasteride (0.6 mg) but feels it's less effective, noticing less hair density and thickness. He is concerned about the effectiveness of the oral treatment compared to the previous combination with topical Minoxidil.
The conversation discusses why CB-03-01, a potential hair loss treatment, isn't widely discussed despite evidence of its effectiveness and safety. Some users mention other treatments like melatonin, procianidin b2, and RU58841, debating their effectiveness and safety.